Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

被引：1
作者：
Delimpasi, Sosana [1 ,2 ]
Dimopoulos, Meletios A. [3 ]
Straub, Jan [4 ]
Symeonidis, Argiris [5 ]
Hajek, Roman [6 ,7 ]
Touzeau, Cyrille [8 ]
Bhanderi, Viralkumar K. [9 ]
Berdeja, Jesus [10 ]
Pavlicek, Petr [11 ]
Matous, Jeffrey, V [12 ,13 ]
Robak, Pawel J. [14 ,15 ]
Suryanarayan, Kaveri [16 ]
Villareal, Miguel [16 ]
Cherepanov, Dasha [1 ,2 ,3 ]
Srimani, Jaydeep K. [16 ]
Yao, Huilan [16 ]
Labotka, Richard [16 ]
Orlowski, Robert Z. [17 ,18 ]
机构：
[1] Gen Hosp Evangelismos, Dept Hematol, Athens, Greece
[2] Gen Hosp Evangelismos, Bone Marrow Transplantat Unit, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
[4] Univ Hosp, Dept Internal Med Hematol, Prague, Czech Republic
[5] Univ Gen Hosp Patras, Dept Hematol, Patras, Greece
[6] Univ Hosp Ostrava, Ostrava, Czech Republic
[7] Univ Ostrava, Fac Med, Ostrava, Czech Republic
[8] Univ Hosp Hotel Dieu, Nantes, France
[9] Tallahassee Canc Ctr, Florida Canc Specialists, Tallahassee, FL USA
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Univ Hosp Kralovske Vinohrady, Dept Internal Med & Hematol, Prague, Czech Republic
[12] Colorado Blood Canc Inst, Denver, CO USA
[13] Sarah Cannon Res Inst, Denver, CO USA
[14] Med Univ Lodz, Dept Hematol, Lodz, Poland
[15] Copernicus Mem Hosp, Lodz, Poland
[16] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[18] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163092
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9995 / 9997
页数：3
相关论文
共 50 条
  • [31] Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide-Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Handa, Hiroshi
    Suzuki, Kenshi
    Chou, Takaaki
    Matsushima, Takafumi
    BLOOD, 2014, 124 (21)
  • [32] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
  • [33] Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study
    Bahlis, Nizar
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus
    Shustik, Jesse
    Schiller, Gary
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S162 - S162
  • [34] Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
    Laubach, Jacob P.
    Schjesvold, Fredrik
    Mariz, Mario
    Dimopoulos, Meletios A.
    Lech-Maranda, Ewa
    Spicka, Ivan
    Hungria, Vania T. M.
    Shelekhova, Tatiana
    Abdo, Andre
    Jacobasch, Lutz
    Polprasert, Chantana
    Hajek, Roman
    Illes, Arpad
    Wrobel, Tomasz
    Sureda, Anna
    Beksac, Meral
    Goncalves, Iara Z.
    Blade, Joan
    Rajkumar, S. Vincent
    Chari, Ajai
    Lonial, Sagar
    Spencer, Andrew
    Maison-Blanche, Pierre
    Moreau, Philippe
    San-Miguel, Jesus F.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2021, 22 (01) : 142 - 154
  • [35] MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED/REFRACTORY TO PRIOR ALKYLATORS - A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES
    Larocca, A.
    Rodriguez-Otero, P.
    Mateos, M.
    Oriol, A.
    Blade, J.
    Cavo, M.
    Leleu, X.
    Nadeem, O.
    Hiemenz, J. W.
    Hassoun, H.
    Touzeau, C.
    Alegre, A.
    Paner, A.
    Maisel, C.
    Mazumder, A.
    Raptis, A.
    Thuresson, M.
    Harmenberg, J.
    Harlin, O.
    Richardson, P. G.
    HAEMATOLOGICA, 2021, 106 (10) : 72 - 73
  • [36] Efficacy and safety of pomalidomide and dexamethasone (Pd) for Chinese patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, single-arm, phase II study
    Lu, J.
    Fu, W-J.
    Wang, Y-F.
    Zhao, H-G.
    Niu, T.
    Fang, B-J.
    Liao, A-J.
    Bai, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S781 - S782
  • [37] Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial
    Weisel, Katja
    Dimopoulos, Meletios
    Oriol, Albert
    Beksac, Meral
    Schjesvold, Frederick
    Liberati, Anna Marina
    Lindsay, Jindriska
    White, Darrell
    San-Miguel, Jesus
    Moreau, Philippe
    Anderson, Larry D., Jr.
    Lorocca, Alessandra
    Robak, Pawel
    Vogel, Prisca
    Jiang, Ruiyun
    Grote, Lara
    Peluso, Teresa
    Richardson, Paul
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 166
  • [38] Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
    Mateos, Maria-Victoria
    Masszi, Tamas
    Grzasko, Norbert
    Hansson, Markus
    Sandhu, Irwindeep
    Pour, Ludek
    Viterbo, Luisa
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Hamadani, Mehdi
    Borsaru, Gabriela
    Berg, Deborah
    Lin, Jianchang
    Di Bacco, Alessandra
    van de Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    HAEMATOLOGICA, 2017, 102 (10) : 1767 - 1775
  • [39] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
    Hari, P.
    Shain, K. H.
    Voorhees, P.
    Gabrail, N.
    Abidi, M.
    Zonder, J.
    Boccia, R.
    Richardson, P. G.
    Neuman, L.
    Wong, H.
    Dixon, S.
    Prada, C. P.
    HAEMATOLOGICA, 2015, 100 : 254 - 255
12345